TRCT
PHIO icon

Tower Research Capital (TRC)’s Phio Pharmaceuticals PHIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.3K Buy
+7,620
New +$8.69K ﹤0.01% 3933
2025
Q4 		– Sell
-406
Closed -$1.01K – 5479
2025
Q3 		$1.01K Buy
+406
New +$924 ﹤0.01% 4894
2025
Q2 		– Sell
-2,501
Closed -$3.25K – 5503
2025
Q1 		$3.25K Sell
2,501
-2,181
-47% -$4.03K ﹤0.01% 4445
2024
Q4 		$8.43K Buy
4,682
+3,508
+299% +$9.53K ﹤0.01% 3995
2024
Q3 		$4.05K Buy
1,174
+537
+84% +$1.93K ﹤0.01% 4700
2024
Q2 		$3.97K Buy
637
+4
+0.6% +$26 ﹤0.01% 4838
2024
Q1 		$3.87K Sell
633
-2
-0.3% -$14 ﹤0.01% 4777
2023
Q4 		$4.34K Buy
635
+412
+185% +$4.23K ﹤0.01% 4965
2023
Q3 		$3.03K Buy
223
+76
+52% +$1.58K ﹤0.01% 5064
2023
Q2 		$3.8K Buy
+147
New +$5.16K ﹤0.01% 5022
2023
Q1 		– Sell
-48
Closed -$2K – 6177
2022
Q4 		$2K Sell
48
-3
-6% -$154 ﹤0.01% 5406
2022
Q3 		$3K Sell
51
-25
-33% -$1.89K ﹤0.01% 5412
2022
Q2 		$6K Buy
+76
New +$7.14K ﹤0.01% 4941
2021
Q3 		– Sell
-6
Closed -$2K – 6064
2021
Q2 		$2K Buy
+6
New +$1.48K ﹤0.01% 5064
2020
Q4 		– Sell
-5
Closed -$1K – 5348
2020
Q3 		$1K Buy
+5
New +$1.27K ﹤0.01% 4722
2018
Q4 		– Hold
0
– – – 4229
2018
Q3 		– Hold
0
– – – 4141
2016
Q4 		– Hold
0
– -$1K – 4262
2016
Q3 		– Hold
0
– – – 3343
2016
Q1 		– Hold
0
– – – 4726
2015
Q4 		– Hold
0
– – – 4918
2015
Q1 		– Hold
0
– -$5K – 4805
2014
Q4 		– Hold
0
– – – 2735
2014
Q3 		– Hold
0
– -$5K – 4782
2014
Q2 		– Hold
0
– – – 2867
2014
Q1 		– Hold
0
– – – 2010

Other funds holding PHIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Tower Research Capital (TRC)'s PHIO Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Phio Pharmaceuticals (PHIO) in Q1 2026: 7,620 shares worth $9.3K. The stake represents ﹤0.01% of the portfolio and ranks #3933 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in PHIO as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in PHIO in Q3 2020 and has held it in 15 quarters since. 24 funds tracked by Wall St. Rank hold PHIO as of Q1 2026.

  • Tower Research Capital (TRC) held 7,620 shares of Phio Pharmaceuticals worth $9.3K as of Q1 2026.
  • Phio Pharmaceuticals was a new Tower Research Capital (TRC) position in Q1 2026.
  • Phio Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3933 holding.
  • Tower Research Capital (TRC) first reported a position in Phio Pharmaceuticals in Q3 2020 and has held it in 15 quarters since.
  • 24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.